Stephanie A. Haddad, Hematology/Oncology Fellow Physician and Wellness Chief Fellow at Mays Cancer Center at UT Health San Antonio, shared a post on LinkedIn:
“Day 5 of ASCO26 getting ready to head back to San Antonio and reflecting on some of the Breast Cancer Highlights from ASCO2026 ASCO Featured Voice
- SERENA-6: ctDNA-detected ESR1 mutations now guide early switch to camizestrant before radiographic progression in HR+/HER2− mBC
- DESTINY-Breast09: T-DXd continues to challenge taxane-based regimens in frontline HER2+ mBC
- ASCENT-04: SG + pembrolizumab positions itself as a new 1L standard for PD-L1+ mTNBC
- TROPION-Breast02: Dato-DXd further defines its role in the TROP2-ADC landscape
- OPTIMA and de-escalation trials: Expanding the use of genomic risk stratification to safely reduce chemotherapy exposure in select patients with early-stage HR+/HER2− disease.”
More posts featuring Stephanie A. Haddad.